CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Abilify® Tablets (Aripiprazole tablets), 2, 5, 10, 15, 20 and 30mg.  The product is available for shipment now.

Aripiprazole tablets are are indicated for the following: (A) Bipolar I disorder, (B) Irritability, associated with autistic disorder; (C) Major depressive disorder; (D) Schizophrenia and (E) Tourette disorder.

“The approval of Aripiprazole tablets supports our commitment to developing affordable, high quality generic products within the CNS therapeutic space” said Hai Wang, President of Solco Healthcare.

According to IQVIA, U.S. brand and generic sales of Aripiprazole tablets were approximately $985.1 million for the 12 months ending in December 2017.